Virtual twin approach using physiologically based pharmacokinetic modelling in hospitalized patients treated with apixaban or rivaroxaban
Open Access
- 4 March 2025
- journal article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 91 (7) , 2057-2069
Abstract
Aims: In a large cohort of hospitalized patients, previously validated physiologically based pharmacokinetic (PBPK)‐based models for apixaban and rivaroxaban are being assessed for their performance in predicting individual pharmacokinetics, aiming to identify patients at high risk of under‐ or overdosing based on demographic, physiological and CYP‐related phenotypic characteristics. Methods: Clinical data were collected from hospitalized patients treated with apixaban ( n = 100) or rivaroxaban ( n = 100) at the Geneva University Hospitals (HUG). These patients were recruited in the OptimAT trial (NCT03477331). PBPK modelling created virtual twins for each patient, integrating demographic, kidney function, P‐glycoprotein (Pgp) and cytochrome P450 (CYP450) 3A phenotyping. Individual PK profiles were simulated for every patient and compared to actual drug exposure, as assessed with LC/MS–MS. Results: Mean fold error (MFE) (95% CI) for the apixaban and rivaroxaban models integrating demographic and kidney function was within the pre‐required bioequivalency criteria with 1.10 (1.04–1.16) and 0.97 (0.93–1.02), respectively. Adding individual Pgp and CYP3A phenotypes led to a slight overprediction 1.25 (1.17–1.33) and 1.30 (1.21–1.39), but patients at risk for bleeding were correctly predicted with MFEs of 0.90 (0.76–1.04) and 1.15 (1.11–1.20). Conclusions: In a large cohort of hospitalized patients, a PBPK model incorporating demographic characteristics and kidney function can accurately predict, within bioequivalency criteria, an individual's apixaban and rivaroxaban plasma exposure. The added value of individual Pgp and 3A phenotypes on the predictive performance need to be further explored, although patients at higher risk for bleeding may benefit. This innovative approach represents an important step towards the application of PBPK at bedside.Keywords
Funding Information
- Hôpitaux Universitaires de Genève
This publication has 37 references indexed in Scilit:
- Impact of Direct Oral Anticoagulant Concentration on Clinical Outcomes in Asian Patients with Atrial FibrillationClinical Pharmacology & Therapeutics, 2023
- Effect of Genotype on the Pharmacokinetics and Bleeding Events of Direct Oral Anticoagulants: A Systematic Review and Meta‐analysisThe Journal of Clinical Pharmacology, 2022
- Population Pharmacokinetic Models for Direct Oral Anticoagulants: A Systematic Review and Clinical Appraisal Using Exposure SimulationClinical Pharmacology & Therapeutics, 2022
- Data‐driven personalization of a physiologically based pharmacokinetic model for caffeine: A systematic assessmentCPT: Pharmacometrics & Systems Pharmacology, 2021
- Physiologically‐Based Pharmacokinetic Modeling for the Prediction of a Drug–Drug Interaction of Combined Effects on P‐glycoprotein and Cytochrome P450 3ACPT: Pharmacometrics & Systems Pharmacology, 2020
- Virtual Twins: Understanding the Data Required for Model‐Informed Precision DosingClinical Pharmacology & Therapeutics, 2020
- Next Challenge From the Variance in Individual Physiologically‐Based Pharmacokinetic Model‐Predicted to Observed Morphine Concentration in Critically Ill NeonatesClinical Pharmacology & Therapeutics, 2019
- Improving Public Health Requires Inclusion of Underrepresented Populations in ResearchJAMA, 2018
- Laboratory Monitoring of Non–Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial FibrillationJAMA Cardiology, 2017
- Why Has Model‐Informed Precision Dosing Not Yet Become Common Clinical Reality? Lessons From the Past and a Roadmap for the FutureClinical Pharmacology & Therapeutics, 2017